December 11, 2015.
Clinical researchers at St George’s, University of London, U.K. have used crowd-funding methods based on donations and rewards to raise cash for a Phase II trial in 140 bowel cancer patients on the FutSci platform.
The campaign has reached its target of £50,000 (approximately $75K) in the first 45 days, according to Dr Deepika Kassen, PhD, Director of FutSci. To date it has been backed by 320 people from 16 countries and has raised £53,088.88 ($80564.76). There are still 10 days left of the campaign.
Scientists plan to use the funds to repurpose Artesunate, an antimalarial drug discovered by Nobel Prize Laureate (2015) Tu Youyou, in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.
The campaign is a collaboration between the researchers, FutSci, Bowel Disease UK and the Anticancer Fund. The researchers are using the money to top-up funds they already have from charity. Budget cuts mean the research is not funded by government/institutional bodies, and the pharmaceutical industry is not interested because it is a relatively cheap drug, noted Kassen.
More information is available at www.futsci.com/project/antimalarial-cancer.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.